SONY

Product Data Sheet

FITC anti-mouse CD16.2 (FcγRIV)

Catalog # / Size: 1347565 / 25 µg
1347570 / 100 µg

Clone: 9E9

Isotype: Hamster IgG

Immunogen: FCγR4 Ã¢â‚¬â€œEC domain fusion with IgG1 Fc

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: Lot-specific



C57BL/6 mouse bone marrow cells were stained with CD16.2 (clone 9E9) FITC (filled histogram) or FITC Armenian Hamster IgG isotype control (open histogram). Histograms shown are gated on the myeloid population.

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 microg per million cells in 100 microL volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: Additional reported applications (for the relevant formats of this clone) include: blocking of FcγRIV function1 and inhibition of immune complex binding[1,2]. The LEAF™ or Ultra-LEAF™ purified antibody (Endotoxin < EU/microg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (contact our custom solutions team).

Application References:
1. Mancardi DA, *et al.* 2008. *J. Clin. Invest* 118:3738. (FC, Block)
2. Nimmerjahn F, *et al.* 2005. *Immunity* 23:41.

Description: FcγRIV, also known as CD16.2, is an intermediate-affinity activating receptor for IgG2a and IgG2b. CD16.2 is the mouse homolog of human FcγRIIIA. CD16.2 is a low-affinity IgE receptor for all allotypes and the ligation of FcγRIV by antigen-IgE immune complexes promotes macrophage-mediated phagocytosis and is involved in lung inflammation.

Antigen References:
1. Mechetina LV, *et al.* 2002. *Immunogenetics* 54:463-8.
2. Nimmerjahn F, *et al.* 2005. *Immunity* 23:41-51.
3. Seeling M, *et al.* 2013. *Proc. Natl. Acad. Sci.* 110:10729.